Sripathi M. Sureban, M. Pharm, Ph.D.

Present Position:

1. **Assistant Professor of Research** (Digestive Diseases and Nutrition), The University of Oklahoma Health Sciences Center.
2. **Associate Member, Peggy and Charles Stephenson Cancer Center** at The University of Oklahoma.
3. **Research Co-investigator**, Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104.
4. **Member of Review Committee of The Institutional Animal Care and Use Committee (IACUC)**, The University of Oklahoma Health Sciences Center.
5. **Research Investigator/Scientific Consultant**, COARE Biotechnology Inc.

Key words: Cancer, Cancer stem cells, Pluripotency, microRNAs, Gene regulation, Epithelial-mesenchymal transition (EMT), siRNA, RNA-binding proteins, Epigenetics, Pancreatic cancer, Colorectal cancer, Liver cancer, Hepatitis B Virus treatment, and Clinical trials.

Education:

Diploma: 1993, **Diploma in Pharmacy,** Board of Examining Authority, Drugs Control Department, Govt. of Karnataka, PES College of Pharmacy, Bangalore, India.

Undergraduate: 1997, **Bachelor of Pharmacy,** Bangalore University, St. John's college of Pharmacy, Bangalore, India.

Graduate: 1999, **Master of Pharmacy (Pharmacognosy)**, Rajiv Gandhi University of Health Sciences, Department of Pharmacognosy, Govt. College of Pharmacy, Bangalore, India. **Thesis:** Isolation and Standardisation of Markers from *Phyllanthus amarus*. **Mentor:** Uma D. Murthy, Ph.D.

Graduate: 2004, **Doctor of Philosophy (Ph.D.)** Pharmacognosy – Microbiology Inter-disciplinary, Department of Medical Microbiology, University of Madras, Chennai, India. **Thesis:** Studies on Chemical and Biological Standardisation of *Phyllanthus amarus* and its Formulation for the use in the Treatment of Chronic Hepatitis B.

Mentor: S.P. Thyagarajan, Ph.D., M.D., D.Sc.

Address and Telephone Numbers:

Office: Department of Medicine, Division of Digestive Diseases and Nutrition
The University Oklahoma Health Sciences Center
975, NE 10th Street, BRC 1264, Oklahoma City, OK 73104.
Tel: (405) 271-2175, Fax: (405) 271-5450.
E. Mail: sripathi-sureban@ouhsc.edu

Residence: 14300, N Pennsylvania Avenue, Apt 60,
Oklahoma City, OK 73134. Tel: (405) 496-3106 (Cell).
E. Mail: mssripathi@gmail.com

Profile:

OUHSC/Cancer Center:	http://stephenson.pure.elsevier.com/en/persons/sripathi-sureban%2843a5f180-8839-43ac-8e3f-ddfb091c1bcf%29.html
Research gate:	http://www.researchgate.net/profile/Sripathi_Sureban/
Google Scholar:	http://scholar.google.com/citations?hl=en&user=kEvSEEMAAAAJ
LinkedIn:	https://www.linkedin.com/pub/sripathi-sureban/69/555/4a0

Professional Experience:

1997-1999	**Junior Research Fellow**, *Rajiv Gandhi University of Health Sciences* and **Research Fellow**, *Natural Remedies Pvt. Ltd (a Biotech Company)*.
1999-2003	**Senior Research Fellow**, *University of Madras* and **Research Fellow**, *Rallis India Ltd; Amadeus Biotech & Pharmaceuticals*.
Nov 2003-Oct 2004	**Research Scholar,** Department of Internal Medicine, Division of Gastroenterology, *Washington University School of Medicine*, St. Louis, MO. **Mentor:** Dr. Shrikant Anant, Ph.D.
Nov 2004-Jun 2006	**Post Doctoral Research Fellow**, Department of Internal Medicine, Division of Gastroenterology, *Washington University School of Medicine*, St. Louis, MO. **Mentor:** Dr. Shrikant Anant, Ph.D.
Jul 2006-Feb 2011	**Post Doctoral Research Fellow**, Department of Medicine, Division of Digestive Diseases and Nutrition, *The University of Oklahoma Health Sciences Center*, Oklahoma City, OK 73104. **Mentor:** Dr. Courtney W. Houchen, M.D. Chief of Digestive Diseases and Nutrition
Mar 2011-present	**Assistant Professor of Research**, Department of Medicine, Division of Digestive Diseases and Nutrition, *The University of Oklahoma Health Sciences Center*, Oklahoma City, OK 73104.
Sept 2008-present	**Research co-investigator** (VA Research staff), *Department of Veterans Affairs Medical Center*, Oklahoma City, OK 73104. **Principal Investigator:** Dr. Courtney W. Houchen, M.D.
Jan 2010-present	**Member of Review Committee of The Institutional Animal Care and Use Committee (IACUC)**, *The University of Oklahoma Health Sciences Center*.
Jun 2012-present	**Associate Member, Peggy and Charles Stephenson Cancer Center** at *The University of Oklahoma*.
Jun 2008-Jun 2010	**Research Investigator/Scientific Consultant,** *ADNA Inc*.
Jun 2010-present	**Research Investigator/Scientific Consultant,** *COARE Biotechnology Inc*.
Nov 2009-Apr 2013	**Editor-in-Chief,** Journal of Basic and Clinical Pharmacy, (http://www.jbclinpharm.org/)

Editorial Responsibilities:

Grant Reviews:

Scientific grant reviewer for Oak Ridge Associated Universities (ORAU), 2013 – present.
North West Cancer Research, Liverpool, UK, 2013 – present.
Sultan Qaboos University, Muscat, Sultanate of Oman, 2014 – present.

International Scientific Journals:

- **Editor** of Pancreatic Disorders and Therapy, 2011 – present.
- **Editor-in-Chief** of Journal of Basic and Clinical Pharmacy (Wolters Kluwer), 2009 – 2013.
- Ad-hoc Reviewer, Cancer Research, 2010 – present.
- Ad-hoc Reviewer, Clinical Cancer Research, 2011 – present.
- Ad-hoc Reviewer, Stem Cells, 2013 – present.
- Ad-hoc Reviewer, American Journal of Gastroenterology, 2011 – present.
- Ad-hoc Reviewer, British Journal of Cancer, 2012 – present.
- Ad-hoc Reviewer, Nature – Clinical and Translational Gastroenterology, 2011 – present.
- Ad-hoc Reviewer, International Journal of Cancer, 2012 – present.
- Ad-hoc Reviewer, Bioresource Technology, 2008 – present.
- Ad-hoc Reviewer, PLoS One, 2012 – present.
- Ad-hoc Reviewer, BMC Cancer, 2014 – present.
- Ad-hoc Reviewer, Nutrition and Cancer, 2104 – present.
- Ad-hoc Reviewer, Journal of Gastroenterology and Hepatology, 2008 – present.
- Ad-hoc Reviewer, Journal of Experimental & Clinical Cancer Research, 2010 – present.
- Ad-hoc Reviewer, Natural Product Research, 2011 – present.
- Ad-hoc Reviewer, African Journal of Microbiology Research, 2010 – present.

External examiner for graduate thesis evaluation:

1. Manipal University, Manipal, Karnataka, India. 2010 – present.
2. Vinayaka Mission University, Salem, Tamil Nadu, India. 2012 – present.

Honors and Awards:

1997	First Rank, B. Pharmacy, St. Johns College of Pharmacy, Bangalore University.
1997	90 percentile in Graduate Aptitude Test in Engineering with an all India ranking of 200.
1997-1999	All India Council for Technical Education Fellowship.
1997-1999	Masters Research Sponsor: Natural Remedies Private Limited, Bangalore, India.
1999-2003	Ph.D. Research Sponsors: Amadeus Pharmaceutical and Biotech Private limited, Mumbai, India and Phytopharm Plc., Huntingdon, U.K.
2004	Indira Vasudevan Award for the best paper presentation at 25th Annual conference of the Indian Association of Biomedical Scientists, Chennai, India.
2006	Fellow Abstract of the Year Award for best abstract and best presentation, Digestive Disease Week 2006 conference at LA. Awarded by American Gastroenterology Association (AGA) and Foundation for Digestive Health and Nutrition (FDHN).

2006 Fellow Travel Award, Digestive Disease Week 2006 conference at LA, awarded by Gastroenterology Research Group (GRG) and AGA.
2011 OUHSC Faculty Senate Award for successful award and publishing of US patent application # 7,902,166 B2.
2012 OUHSC Faculty Senate Award for successful award and publishing of US patent application # 7,956,044 B1.
2013 OUHSC Faculty Senate Award for successful award and publishing of US patent application # 8,198,255.

Professional Societies and Organizations:

- Member of the American Gastroenterological Association, 2004 – present.
- Member of the Gastroenterology Research Group, 2006 – present.
- Member of the American Association for Cancer Research, 2009 – present.
- Member of the American Pancreatic Association, 2010 – present.
- Member of Indian Association of Medical Microbiologist, 2000 – present.
- Member of the Indian Association of Biomedical Scientists, 2003 – present.

Patents/Invention Disclosures and Press Coverage:

1. siRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1. **US Patent # 8,198,255,** awarded June 12, 2012. Inventors: Houchen, Courtney; May, Randal; Anant, Shrikant and **Sureban, Sripathi M**. ***(Ref: Sureban et al., Gastroenterology. 2009;137(2):649-59; May et al., Stem Cells. 2008;26(3):630-7.)***
   This research work was officially released to press (Oklahoma state new channels and newspapers) after filing the patent application on April 28th 2008. Facilitated with an award during the OUHSC Faculty senate award ceremony on April, 29rd, 2013.
2. Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same. **US Patent # 7,956,044 B1,** awarded June 7, 2011. (Invention disclosure title: RNA binding protein Musashi-1 is an essential regulator of tumor growth) Inventors: Houchen, Courtney; Anant, Shrikant and **Sureban, Sripathi M**. ***(Ref: Sureban et al., Gastroenterology. 2008;134(5):1448-58.)***
   This research work was officially released to press (Oklahoma state new channels and newspapers) after filing the patent application on March 20th 2008. Facilitated with an award during the OUHSC Faculty senate award ceremony on April, 23rd, 2012.
3. Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same. **US Patent # 7,902,166 B2,** awarded March 8, 2011. (Invention disclosure title: RNA binding protein RBM3 is an essential regulator of tumor growth). Inventors: Houchen, Courtney; Anant, Shrikant; **Sureban, Sripathi M.**; Ramalingam, Satish; Subramaniam, Dhamalingam and Ramanujam, Rama. ***(Ref: Sureban et al., Oncogene. 2008;27(33):4544-56.)***
   This research work was officially released to press (Oklahoma state new channels and newspapers) after filing the patent application on April 20th 2008. Facilitated with an award during the OUHSC Faculty senate award ceremony on April, 29th, 2011.

4. Anti-DCLK1 monoclonal antibodies and methods of production and use thereof. **US Patent application # 20140056972** published on February 27, 2014. Inventors: Houchen, Courtney; **Sureban, Sripathi M.**; May, Randal; Qu, Dongfeng and Weygant, Nathaniel.

5. Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof. **Invention disclosure** submitted on Feb, 2013 to the OUHSC. Inventors: Houchen, Courtney; **Sureban, Sripathi M.**; May, Randal; Qu, Dongfeng; Berry, William and Weygant, Nathaniel.

6. Targeting stem cells in Barrett's esophagus and esophageal cancer. **Invention disclosure** submitted on Nov, 2010 to the OUSHC. Inventors: Houchen, Courtney; Vega, Kenneth; Whorton, Joshua; May, Randal; **Sureban, Sripathi M.**; Tierney, William; Johnson, Milton and Maple, John. ***(Ref: Whorton et al., Digestive Diseases and Sciences. 2014 Oct 5.)***

7. Targeting liver stem and progenitor cells in Hepatitis C, B and hepatocellular carcinoma. **Invention disclosure** submitted on Nov, 2010 to the OUHSC. Inventors: Houchen, Courtney; Ali, Naushad; **Sureban, Sripathi M.** and May, Randal. ***(Ref: Ali et al., Journal of Virology. 2011;85(23):12292-303.)***

8. Nanoparticle-loaded siRNA against cancer-stem cells. **Invention disclosure** submitted on Aug, 2010 to the OUHSC. Inventors: Houchen, Courtney; May, Randal and **Sureban, Sripathi M**. ***(Ref: Sureban et al., Journal of Nanobiotechnology. 2011;19(9):40.)***

9. Therapeutic uses of Phyllanthin and Hypophyllanthin for treating cancer diseases of colon and liver, **Provisional Patent** filed in Dec 2005 to the Washington University. Inventors: Anant, Shrikant; **Sureban, Sripathi M.** and Dieckgraefe, Brian K. ***(Ref: Sureban et al., Journal of Pharmacology and Toxicology. 2006;1(4):65-71.)***

Grant Funding:

Active:

NIH/NCI – R21 (**Role – Key Personnel**) **Houchen (PI)** (12/01/14 – 11/30/16)
Title: Targeting DCLK1 kinase activity in pancreatic cancer. **Goal:** Goal is to assess the feasibility of using the small molecule inhibitor XMD8-92 that block DCLK1 kinase activity as a new therapeutic approach to improve PDAC treatment outcomes.

NIH/NIDDK – U01: (**Role – Key Personnel**) **Houchen (PI)** (09/01/09 – 09/31/15)
Title: Isolation and Characterization of Intestinal Stem Cells Using Novel Markers. **Goals:** The major goal of this proposal is to isolate intestinal stem cells (ISCs) from the mouse intestine in order to elucidate the molecular features that distinguish ISCs from their immediate descendants, the progenitor and transit-amplifying cells.

DoD - CDMRP – Discovery award: (**Role – Key Personnel**) **Houchen (PI)** (10/01/12 – 2/28/15)

Title: Tuft cell regulation of miRNAs in Pancreatic Cancer. **Goal:** The fundamental goal of this proposal is to demonstrate that pancreatic tuft cells are the cells of origin for pancreatic cancer and perhaps other solid tumors.

NIH/SBIR: (**Role – Key Personnel – OUHSC Sub-contract**) **Pantazis (PI)** (07/01/13 – 02/28/15)
Title: Development of monoclonal antibodies to treat Pancreatic cancer. **Goal:** Goal is to assess the feasibility of using a novel mAb, CBT-1111 (a mouse anti-human DCLK1 monoclonal antibody) as a new therapeutic to improve PDAC treatment outcomes.

Veterans Affairs Merit Review: **(Role – Key Personnel) Houchen (PI)** (10/01/2013 – 09/30/17)
Title: The Gastrointestinal Stem Cell Response to Injury. **Goals:** The fundamental goals are to determine whether DCLK1 plays a key role in regulating the rescue stem cell population in response to severe genotoxic and potentially mutagenic injury, and these "rescue/reserve" cells are potential cells of origin that can contribute to gastrointestinal neoplasia.

Presbyterian Health Foundation (PHF) **(Role – Key Personnel) Houchen (PI)** (10/01/14 – 09/30/15)
Title: The role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma.
Goal: The fundamental goal of this project is to understand the role of cancer stem cells, cancer stem cell marker, and target cancer stem cells in pancreatic adenocarcinoma.

NIH/SBIR (**Role – Key Personnel – OUHSC Sub-contract**) **Schlosser (PI)** (02/01/15 – 12/31/15)
Title: Development of an ADC against pancreatic cancer. **Goal:** The fundamental goal of this SBIR proposal is to assess the feasibility of developing a new therapeutic agent (antibody drug conjugate) (CBT-3112 – mouse anti-human monoclonal antibody raised against extracellular domain of DCLK1 conjugated with Paclitaxel) that targets DCLK1 expressing cells, cancer related pathways, and critical processes for the treatment of ductal adenocarcinoma (PDAC).

NIH/SBIR (**Role – Key Personnel – OUHSC Sub-contract**) **Schlosser (PI)** (04/01/15 – 12/31/15)
Title: Development of ADC to target tumor stem cells in colorectal cancer. **Goal:** The fundamental goal of this Phase I SBIR proposal is to assess the feasibility of developing a new therapeutic agent (antibody drug conjugate) (CBT-3112 – mouse anti-human monoclonal antibody raised against extracellular domain of DCLK1 conjugated with Paclitaxel) that targets doublecortin-like kinase 1 (DCLK1) expressing cells, cancer related pathways, and critical processes for the treatment of advanced colorectal cancers (CRC).

Pending:

Oklahoma Center for the Advancement of Science & Technology (**Role – PI) Sureban (PI)** (04/1/15 – 03/31/18)
Title: Role of Musashi-1 in pancreatic cancer. **Goals:** The fundamental goal of this research proposal is to determine the mechanistic role by which Musashi-1 (MSI1) regulates cMYC and COX2 in human pancreatic cancer.

NIH/SBIR (**Role – Key Personnel – OUHSC Sub-contract**) **Schlosser (PI)** (02/01/15 – 12/31/15)
Title: Development of novel agents that target DCLK1 expressing cancer stem cells. **Goal:** The fundamental goal of this contract proposal is to design develop and ultimately commercialize new

therapeutic agent (CBT-311 – PLGA nanoparticle encapsulated siRNA against DCLK1) that target cancer stem cells and cancer related pathways and critical processes for the treatment of ductal adenocarcinoma (PDAC).

Past Funding:

Oklahoma Center for Adult Stem Cell: **(Role – Co-PI) Houchen (PI)** (01/01/2011 – 06/20/2012) **Title:** Role of Adult Stem Cells in Pancreatic Regeneration and Diabetes Treatment. **Goals:** The major goals are to identify whether DCAMKL-1+ pancreatic stem cells can be converted into insulin-producing beta-cells and to determine their role in pancreatic regeneration.

Bibliography ***(Sureban, S.M., is the lead author in 14 out of 45 publications):***

A. Peer Reviewed Manuscripts:

1. Qu, D., Johnson, J., Chandrakesan, P., Weygant, N., May, R., Aiello, N., Rhim, A., Zhao, L., Zheng, W., Lightfoot, S.A., Pant, S., Irvan, J., Postier, R., Hocker, J., Hanas, J.S., Ali, N., **Sureban, S.M.,** An, G., Schlosser, M.J., Stanger, B., and Houchen, C.W. Serum DCLK1 levels are elevated in pancreatic adenocarcinoma patients. ***PLoS ONE*** *2015 Accepted – In Press*.

2. Weygant, N., Qu, D., May, R., Tierney, R.M., Berry, W.L., Zhao, L., Agarwal, S., Chandrakesan, P., Chinthalapally, H.R., Murphy, N.T., Li, J.D., **Sureban, S.M.,** Schlosser, M.J., Tomasek, J.J., and Houchen, C.W. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. ***Oncotarget*** *2014 Dec 11. PMID: 25605241*.

3. Whorton, J., **Sureban, S.M.,** May, R., Qu, D., Lightfoot, S.A., Madhoun, M., Johnson, M., Tierney, W.M., Maple, J.T., Vega, K.J. and Houchen, C.W. Plasma DCLK1 expression as an early marker of Barrett's esophagus. ***Digestive Diseases and Sciences*** 2015;60(2):509-13. *PMID: 25283374*.

4. **Sureban, S.M.,** Qu, D., Chandrakesan, P., May, R., Weygant, N., Ali, N., Pantazis, P. and Houchen, C.W. Small molecule inhibitor XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. ***Cancer Letters***. 2014;351(1):151-61. *PMID: 24880079*.

5. Weygant, N., Qu, D., Berry, W.L., May, R., Chandrakesan, P., Owen, D.B., **Sureban, S.M.,** Ali, N., Janknecht, R. and Houchen, C.W. Small-molecule Parkinson's disease kinase inhibitor LRRK2-IN-1 demonstrates potent anti-cancer activity through inhibition of doublecortin-like kinase 1. ***Molecular Cancer.*** 2014;13(1):103. *PMID: 24885928*.

6. Chandrakesan, P., May, R., Weygant, N., Qu, D., **Sureban, S.M.,** Ali, N., Murugan, P., Lightfoot, S., Umar, S. and Houchen, C.W. Dclk1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. ***Oncotarget.*** 2014;5(19):9269-80. *PMID: 25211188*.

7. Ramachandran, I., Gillies, E., Fonseca, I., Kaufman, K,M., **Sureban, S.M.,** Houchen, C.W., Reis, A. and Queimado, L. Wnt inhibitory factor 1 inhibits cancer stem cell proliferation and induces cellular senescence in human salivary gland tumors. ***Cell Death & Disease***. 2014;5:e1246. *PMID: 24853424*.

8. Qu, D., May, R., **Sureban, S.M.,** Weygant, N, Chandrakesan, P., Ali, N., Barrett, T, and Houchen, C.W. Notch inhibition reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury. ***American Journal of Physiology-Gastrointestinal and Liver Physiology***. 2014;306(5):G404-11. *PMID: 24368703*.

9. May, R., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., Lightfoot, S.A., Li, L., **Sureban, S.M.** and Houchen, C.W. Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury. ***Stem Cells***. 2014;32(3):822-27. *PMID: 24123696*.

10. Ali, N., Allam, H., Bader, T., May, R., Basalingappa, K.M., Berry, W.L., Chandrakesan, P., Qu, D., Weygant, N., Bronze, M.S., Umar, S., Janknecht, R., **Sureban, S.M.,** Huycke, M. and Houchen, C.W. Fluvastatin interferes with Hepatitis C virus replication via microtubule bundling and a Doublecortin-like kinase-mediated mechanism. ***PLoS ONE***. 2013;8(11):e80304. *PMID: 24260365*.

11. **Sureban, S.M.,** May, R., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., Lightfoot, S.A., Pantazis, P., Brackett, D.J., Rao, C.V., Postier, R.G. and Houchen, C.W. DCLK1 regulates pluripotency and angiogenesis via microRNA dependent mechanisms in pancreatic cancer. ***PLoS ONE***. 2013;8(9):e73940. *PMID: 24040120*.

    This was also published as news in Oklahoma channels 4, 5, 6, 9, 25, OETA – Oklahoma PBS station and state newspaper The Oklahoman.

    http://newsok.com/university-of-oklahoma-research-identifies-key-protein-in-pancreatic-cancer/article/3896795
    http://www.youtube.com/watch?v=veSj9F75Qio

12. Kathiravan, G., **Sureban, S.M.,** Harsha, S., Bhuvaneshwari, V. and Kramony, E. Isolation of anticancer drug Taxol from *Pestaiopsis breviseta* with apoptosis B-cell lymphoma protein docking studies. ***Journal of Basic and Clinical Pharmacy***. 2013;4(1):14-19. *PMID: 24808664*.

13. Vega, K.J., May, R., **Sureban, S.M.,** Qu, D., Reed, A., Lightfoot, S.A., Ramanujam R., Souza, R., Meltzer, S.J., Madhoun, M., Whorton, J., Anant, S. and Houchen, C.W. Identification of the putative intestinal stem cell marker DCAMKL-1 in Barrett's esophagus and esophageal adenocarcinoma. ***Journal of Gastroenterology and Hepatology***. 2012;27(4):773-80. *PMID: 21916995*.

14. Ali, N., Allam, H., May, R., **Sureban, S.M.,** Bronze, M.S., Umar, S Anant, S. and Houchen, C.W. Hepatitis C virus-induced cancer stem cell-like signatures in murine tumor xenografts and cell culture. ***Journal of Virology***. 2011;85(23):12292-303. *PMID: 21937640*.

15. **Sureban, S.M.,** May, R., Mondalek, F.G., Ponnurangam, S., Pantazis, P., Ramanujam, R., Anant, S. and Houchen, C.W. Nanoparticle-based delivery of siDCAMKL-1 increases *microRNA-144* and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. ***Journal of Nanobiotechnology***. 2011;9(1):40. *PMID: 21929751*.
Highly Accessed article according to Journal of Nanobiotechnology.

16. **Sureban, S.M.,** May, R., Lightfoot, S.A., Hoskins, A.B., Brackett, D.J., Postier, R.G., Ramanujam, R., Mohammed, A., Rao, C.V., Wyche, J.H., Anant, S. and Houchen, C.W. DCAMKL-1 regulates human pancreatic cancer epithelial-mesenchymal transition via a *miR-200a* microRNA-dependent mechanism. ***Cancer Research***. 2011;71(6):2328-38. *PMID: 21285251*.

17. May, R., **Sureban, S.M.,** Lightfoot, S.A., Brackett, D.J., Postier, R.G., Ramanujam, R.P., Wyche, J.H., Han, Z., Rao, C.V., Anant, S. and Houchen, C.W. Identification of a novel putative pancreatic stem cell marker DCAMKL-1 in normal mouse pancreas. ***American Journal of Physiology-Gastrointestinal and Liver Physiology***. 2010;299(2):G303-310. *PMID: 20522640*.

18. Bishnupuri, K.S., Luo, Q., Sainathan, S.K., Kikuchi, K., **Sureban, S.M.**, Sabarinathan, M., Gross, J.H., Aden, K., May, R., Houchen, C.W., Anant, S. and Dieckgraefe, B.K. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. ***Gastroenterology***. 2010;138(2):616-626, 626. e1-2. *PMID: 19900450*.

19. Balasubramanian, P., Jayalakshmi, K., Vidhya, N., Prasad, R., Sheriff, K.A., Kathiravan, G., Rajagopal, K. and **Sureban, S.M.** Antiviral activity of ancient system of ayurvedic medicinal plant *Cissus quadrangularis L.* (Vitaceae). ***Journal of Basic and Clinical Pharmacy***. 2010;1(1):37-40. *PMID: 25206252*.

20. Kathiravan, G. and **Sureban, S.M.** Effect of Taxol from *Pestalotiopsis mangiferae* on A549 cells-*In vitro* study. ***Journal of Basic and Clinical Pharmacy***. 2010;1(1):1-9. *PMID: 25206246*.

21. May, R., **Sureban, S.M.,** Hoang N., Riehl T.E., Lightfoot, S.A., Ramanujam, R.P., Wyche J.H., Anant, S. and Houchen, C.W. Novel markers DCAMKL-1 and LGR5 identify quiescent and cycling gut stem cells respectively. ***Stem Cells***. 2009;27(10):2571-2579. *PMID: 19676123*.

22. **Sureban, S.M.,** May, R., Ramalingam, S., Subramaniam, D., Natarajan, G., Wyche, J.H., Anant, S. and Houchen, C.W. Selective blockade of DCAMKL-1 results in tumor growth arrest by a *let-7a* microRNA dependent mechanism. ***Gastroenterology***. 2009;137(2):649-659. *PMID: 19445940*.

23. George, R., Sturmoski, M., May, R., **Sureban, S.M.,** Dieckgraefe, B.K., Anant, S. and Houchen, C.W. Loss of $p21^{Waf\text{-}1/cip1}$ enhances intestinal stem cell survival following radiation injury. ***American Journal of Physiology-Gastrointestinal and Liver Physiology***. 2009;296(2):G245-254. *PMID: 19056768*.

24. **Sureban, S.M.,** Ramalingam, R., Natarajan, G., May, R., Subramaniam, D., Bishnupuri, K.S., Morrison, A.R., Dieckgraefe. B.K., Brackett, D.J., Postier, R.G., Houchen. C.W and Anant, S. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. ***Oncogene***. 2008;27(33):4544-4556. *PMID: 18427544*.

25. **Sureban, S.M.,** May, R., George, R.J., Dieckgraefe, B.K., Ramalingam, S., Natarajan, G., Anant, S. and Houchen, C.W. Knockdown of RNA binding protein musashi-1 leads to tumor regression *in vivo*. ***Gastroenterology***. 2008;134(5):1448-1458. *PMID: 18471519*.

26. May, R., Riehl, T.E., Hunt, C., **Sureban, S.M.,** Anant, S. and Houchen, C.W. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker: doublecortin and CaM kinase-like-1 following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. ***Stem Cells***. 2008;26(3):630-637. *PMID: 18055444*.

27. Subramaniam, D., May, R., **Sureban, S.M.,** Lee, K.B., George, R., Kuppusamy, P., Ramanujam, R.P., Hideg, K., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. Diphenyl difluoroketone: a curcumin derivative with potent *in vivo* anticancer activity. ***Cancer Research***. 2008;68(6): 1962-1969. *PMID: 18339878*.

28. **Sureban, S.M.,** Murmu, N., Rodriguez, P., May, R., Maheshwari, R., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation. ***Gastroenterology***. 2007;132, 1055-1065. *PMID: 17383427*.

29. **Sureban, S.M.,** Subramaniam, D., Rajendran, P., Ramanujam, R.P., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. Therapeutic effects of *Phyllanthus* species: Induction of TNF-α-mediated apoptosis in HepG2 hepatocellular carcinoma cells. ***American Journal of Pharmacology and Toxicology***. 2006;1(4): 65-71.

30. Kanthesh, B.M., Rajendran, P., **Sripathi, M.S.,** Vikram Reddy, E., Gobianand, K. and Raju, S. Syphilis seroprevalence in healthy Irula tribal population of Tamil Nadu. ***Biomedicine***. 2006;26 (1-2), 35-37.

31. Selvanayagam, S., Velmurugan, D., Ravikumar, K., **Sureban, S.M.,** Kumar, P.V. and Rajani, M. Crystal structure of 3a-hydroxy-3,5a,9-trimethyl-1,3,3a,4,5,5a,6,7,8,9b-decahydro-2H-naphtha[1,2c]imidazole-2-one monohydrate from the plant *Sphaeranthus indicus*. ***Analytical Sciences*****.** 2005;21(6), x99-x100.

32. Raghavendra, N.M., Niranjan, M.S., Venkatesh, P., Kumar, B.R., Gowda, P., Narendra, B. and **Sripathi, M.S.** Synthesis and biological activity of some substituted 2-phenyl-quinazolin-4-ones. ***Asian Journal of Chemistry***. 2005;17(1):57-65.

33. Vishwas, M., Dharmarajan, T.S. and **Sripathi, M.S.** Synthesis of newer succinimide derivatives as anti-microbial agents. ***Oriental Journal of Chemistry***. 2003;19(1):201-203.

34. Rajakannan, V., **Sripathi, M.S.,** Selvanayagam, S., Velumurugan, D., Murthy, U.D., Vishwas, M., Thyagarajan, S.P., Shanmugam Sundara Raj, S. and Fun, H-K. Phyllanthin from the plant *Phyllanthus amarus*. ***Acta Crystalographica***. 2003;E59:o203-o205.

35. Rajendran, P., Kannan, I., Kavita R., Selvarani, P., Kanthesh, B.M., Abdul Rahim, M., **Sripathi, M.S.** and Thyagarajan, S.P. Evaluation of specific IgE by an in-house ELISA for house dust and *Aspergillus niger* allergy and its correlation with skin test. ***Indian Journal of Applied Microbiology***. 2003;3:31-34.

36. Thyagarajan, S.P., Jayaram, S., Hari, R., Gopalakrishnan, V., Jeyakumar, P. and **Sripathi, M.S.** Herbal medicines in liver diseases in India. ***Journal of Gastroenterology Hepatology***. 2002;17(s3):S370-S376. *PMID:12472966*.

37. Rajendran, P., Priya, R., Thyagarajan, S.P., Kannan, I., Hari, R., Kanthesh, B.M., Reena Banerjee, Abdul Rahim, M., Saravanan, M.S., Haripriya, V., **Sripathi, M.S.** and Vijayakumar, V. Serological studies in relation to Syphilis, AIDS, Hepatitis B Virus and Hepatitis C Virus infection in patients attending sexually transmitted diseases and intra venous drug users clinics from Chennai, Tamil Nadu, India. ***Indian Journal of Applied Microbiology***. 2002;2:17-22. *PMID: 12472966*.

38. Haripriya, V., Rajendran, P., Thyagarajan, S.P., **Sripathi, M.S.,** Parthiban, R., Ram, C.C., Gopalakrishnan, P.B., Chandraseskhar, G.S. and Rajendran, M. A study on the comparison between clinical and microbiological diagnoses of sexually transmitted diseases. ***Journal of Indian Medical Association***. 2002;100 (6):372-375. *PMID: 12416669*.

B. Invited Reviews, Book Chapters and Editorials:

1. **Sureban, S.M.,** Qu, D. and Houchen, C.W. Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1. Invited review in 'miRNA and Cancer Prevention and Therapeutics Agents'. ***Current Pharmacology Reports.*** 2015 – *In Press*.

2. **Sureban, S.M.,** Qu, D. and Houchen, C.W. Epigenetic variation of stem cell markers in cancer. Invited Book Chapter in 'Epigenetics and Cancer' – 2013;115-128. Springer Netherlands.

3. Qu, D., **Sureban, S.M.** and Houchen, C.W. Epigenetic variants and biomarkers for colon cancer. ***American Journal of Pathology***. 2012;180(6):2205-2207. *PMID: 22542494*.

4. **Sureban, S.M.,** Johnson, J.J. and Houchen, C.W. Cancer stem cells and pluripotency. Editorial. ***Pancreatic Disorders and Therapy***. 2012;2, e108.

5. Anant, S. and **Sureban, S.M.** Cyclooxygenase-2 expression: Regulation at the transcriptional and posttranscriptional levels. Invited Book Chapter in Apoptosis, Cell Signaling and Human Diseases: Molecular Mechanisms: 2007:197-218, Humana Press.

C. News Letter – Journal of Basic and Clinical Pharmacy:

1. **Sureban, S.M.** and Harsha, S. A word from Journal of Basic and Clinical Pharmacy Editor's desk. *Journal of Basic and Clinical Pharmacy*. 2013;4(1):1. *PMID: 24808661*.
2. Harsha, S. and **Sureban, S.M.** Journal of Basic and Clinical Pharmacy signs collaboration agreement with Medknow Publications-Wolters Kluwer Health. *Journal of Basic and Clinical Pharmacy*. 2012;3(4):329. *PMID: 24826044*.

D. Manuscripts Under Review/Submitted:

1. **Sureban, S.M.,** May, R., Qu, D., Chandrakesan, P., Weygant, N., Ali, N., Umar, S., Ramanujam, R. and Houchen CW. Dietary pectin increases intestinal crypt stem cell survival following radiation injury. ***PLoS ONE*** (Under consideration).

2. Qu, D., May, R., Chandrakesan, P., Weygant, N., **Sureban, S.M.,** Ali, N. and Houchen, C.W. Ablation of Dclk1 in intestinal epithelium exacerbates colonic epithelial barrier damage in response to DSS treatment. ***PLoS ONE*** (Under consideration).

3. Madhoun, M.F., May, R., **Sureban, S.M.,** Qu, D., Fazili, J., Hanigan, M., Weygant, N., Ali, N., Chandrakesan, P., Lightfoot, S.A. and Houchen, C.W. DCLK1 expression as an early marker of cirrhosis and HCC. ***BioMed Research International*** (Under review).

4. Weygant, N., Qu, D., Berry, W.L., May, R., Chandrakesan, P., **Sureban, S.M.,** Janknecht, R., and Houchen, C.W. Doublecortin-like kinase 1 promotes colorectal cancer cell proliferation and invasion. 2014. ***Gastroenterology Research and Practice***. (Under review).

5. Chandrakesan, P., May, R., Qu, D., Weygant, N., **Sureban, S.M.,** Owen, D., Ali, N., Quante, M., Wang, T.C., Bronze, M.S., and Houchen, C.W. Isolated Dclk1+ cells reveal the molecular mechanisms of quiescence, pluripotency, and survival in the mouse small intestine. ***Journal of Cell Science*** (Under review).

6. Ali, N., Allam, H., Bader, T., May, R., Basalingappa, K.M., Berry, W.L., Qu, D., Weygant, N., Bronze, M.S., Umar, S., Janknecht, R., **Sureban, S.M.** and Houchen, C.W. Tumor stem cell marker Doublecortin-like kinase 1 regulates S100A9-medited inflammation and induce Hepatocarcinogenesis. ***Cancer Research*** (Under review).

7. **Sureban, S.M.,** May, R., Qu, D. and Houchen, C.W. Role of pancreatic stem cell marker DCLK1 in liver cancer. ***Cancer Research*** (Under preparation).

8. Chandrakesan, P., May, R., **Sureban, S.M.,** Weygant, N., Qu, D. and Houchen, C.W. Functional significance of Dclk1 in the regulation of molecular signaling critical for intestinal epithelial cell functioning/survival following radiation injury. ***Nature*** (Under preparation).

9. Shakir, F., May, R., **Sureban, S.M.,** Lightfoot, S.A., Madhoun, M. and Houchen, C.W. Expression of a novel stem cell marker Doublecortin-like kinase 1 (DCLK1) in human colorectal polyps and adenocarcinoma. ***Gastroenterology*** (Under preparation).

E. Oral presentation (Conference and Invited presentations) (Presenter underlined) (Sureban, S.M., presented 22 out of total 35 presentations and received 3 international awards):

1. May, R., Qu, D., Weygant, N., **Sureban, S.M.,** Lightfoot, S.A., Maple, T., and Houchen, C.W. The absence of pancreatic ductal Dclk1 entirely reverses the progression of cerulean-induced ADM in mice. Abstract submitted for American Pancreatic Association Conference, Hawaii, November 2014. (*Pancreas* 2014;43(8):1389).

2. **Sureban, S.M.,** Qu, D., Chandrakesan, P., May, R., Weygant, N., Ali, N., Pantazis, P. and Houchen, C.W. Small molecule inhibitors XMD8-92 and PV1019 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Abstract submitted for Digestive Disease Week, Orlando, May 2013. (*Gastroenterology* 2013;144(5):S-53).

3. Chandrakesan, P., May, R., Qu, D., Weygant N., **Sureban, S.M.** and Houchen, C.W. Functional significance of Dclk1 in the regulation of molecular signaling critical for intestinal epithelial cell functioning/survival following 24h post radiation injury. Abstract submitted for Digestive Disease Week, Orlando, May 2013. (*Gastroenterology* 2013;144(5):S-78 – S-79).

4. **Sureban, S.M.,** May, R., Qu, D. and Houchen, C.W. RNA binding protein Musashi-1 regulates tumorigenesis and angiogenesis via microRNA-dependent mechanism. Cancer Retreat, Peggy and Charles Stephenson Cancer Institute (The University of Oklahoma Health Sciences Center), March 2013.

5. Ramachandran, I., Obeso, D., **Sureban, S.M.,** Reis, A. and Queimado, L. Wnt inhibitory factor 1 inhibits salivary gland cancer cell growth: Novel findings on senescence and cancer stem cells. Abstract submitted for Cancer Retreat, Peggy and Charles Stephenson Cancer Institute (The University of Oklahoma Health Sciences Center), March 2013.

6. Ali, N., **Sureban, S.M.,** May, R., Allam, H., Bader, T., Bronze, M. and Houchen, C.W. Fluvastatin causes downregulation of HCV replication via a cancer stem cell marker Doublecortin-like kinase and Microtubule bundling. Cancer Retreat, Peggy and Charles Stephenson Cancer Institute (OUHSC), March 2013.

7. **Sureban, S.M.** DCLK1/DCAMKL-1 regulates epithelial-mesenchymal transition and pluripotency in human pancreatic cancer. Invited talk at Department of Cancer and Cell Biology, University of Cincinnati, Dec 2012.

8. Qu, D., **Sureban, S.M.,** May, R., Weygant, N. and Houchen, C.W. DCAMKL-1 regulates Bmi-1 expression in colorectal and pancreatic cancer cells. Abstract submitted for Digestive Disease Week, San Diego, May 2012 (*Gastroenterology* 2012;142(5):S-51).

9. Houchen, C.W., **Sureban, S.M.,** May, R. and Qu, D. MicroRNAs and intestinal neoplasia. Invited talk at FASEB Conference at Steamboat Grand Resort Steamboat Springs, Colorado, Aug 2011.

10. **Sureban, S.M.,** May, R., Qu, D. and Houchen, C.W. Role of putative stem cell marker DCAMKL-1 in pancreatic cancer and EMT. Abstract submitted for the Cancer Retreat, Peggy and Charles Stephenson Cancer Institute (The University of Oklahoma Health Sciences Center), November 2011.

11. **Sureban, S.M.,** May, R., Qu, D., Modalek, F., Asfa, S., Ramanujam, R.P., Anant, S. and Houchen, C.W. Nanoparticle-based delivery of DCAMKL-1 siRNA and DAPT increases *microRNA-144* and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. Abstract submitted for Digestive Disease Week, Chicago, May 2011 (*Gastroenterology* 2011;140(5):S-122).

12. **Sureban, S.M.,** May, R., Qu, D., Asfa, S., Anant, S. and Houchen, C.W. Knockdown of Musashi-1 results in tumor growth arrest through inhibition of c-Myc, Notch-1 and EMT by *let-7a*, *miR-144* and *miR-200a* microRNAs dependent mechanisms respectively. Abstract submitted for Digestive Disease Week, Chicago, May 2011 (*Gastroenterology* 2011;140(5):S-48).

13. **Sureban, S.M.,** Qu, D., May, R., Asfa, S., Anant, S. and Houchen, C.W. Knockdown of DCAMKL-1 results in liver cancer tumor growth arrest through inhibition of c-Myc via *Let-7a* microRNA; inhibits EMT via *miR-200a* microRNA dependent mechanisms. Abstract submitted for Digestive Disease Week, Chicago, May 2011 (*Gastroenterology* 2011;140(5):S-890).

14. Houchen, C.W., **Sureban, S.M.,** May, R., Qu, D., Brackett, D.J., Postier, R.G., Rao, C.V. and Anant, S. Pancreatic cancer: microRNA regulation in the epithelial-mesenchymal transition in human pancreatic cells. Invited talk at Frontiers in Stem Cells in Cancer Conference at Howard University, Washington, DC, March 2011.

15. Houchen, C.W., **Sureban, S.M.,** May, R., Qu, D., Brackett, D.J., Postier, R.G., Rao, C.V. and Anant, S. Pancreatic cancer stem cell marker DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a *miR-200a*-dependent mechanism. Invited talk at Keystone Symposia on 'Stem cells, Cancer and Metastasis', Colorado, March 2011.

16. **Sureban, S.M.,** May, R., Wyche, J.H., Anant, S. and Houchen, C.W. Role of Intestinal stem cell marker DCAMKL-1 in pancreatic cancer. Abstract submitted for Digestive Disease Week, New Orleans, May 2010 (*Gastroenterology*. 2010;138(5):S-61).

17. **Sureban, S.M.,** May, R., Wyche, J.H., Anant, S. and Houchen, C.W. Knockdown of DCAMKL-1 results in tumor growth arrest through inhibition of Notch1 by a *miR-144* microRNA dependent mechanism. Abstract submitted for Digestive Disease Week, New Orleans, May 2010 (*Gastroenterology*. 2010;138(5):S-49).

18. Houchen, C.W., **Sureban, S.M.,** May, R., Qu, D. and Anant, S. Novel markers for intestinal stem cells. Invited talk at Digestive Disease Week, New Orleans, May 2010. (*Gastroenterology*. 2010;138(5):S-52).

19. May, R., **Sureban, S.M.,** Lightfoot, S.A., Brackett, D.J., Postier, R.G., Ramanujam, R.P., Wyche, J.H., Han, Z., Rao, C.V., Anant, S. and Houchen, C.W. Identification of a novel

pancreatic stem cell marker DCAMKL-1 in mouse pancreas and in pancreatic cancer. Abstract submitted for Digestive Disease Week, Chicago, May 2009 (*Gastroenterology*. 2009;136(5):A-10).

20. Natarajan, G., Ramalingam, S., **Sureban, S.M.,** May, R., Houchen, C.W. and Anant, S. RNA binding protein RBM3: A novel protooncogene required for tumor cells to overcome G2/M arrest and mitotic catastrophe. Abstract submitted for Digestive Disease Week, San Diego, April 2008 (*Gastroenterology*. 2009;136(5):A-86).

21. May, R., **Sureban, S.M.,** Anant, S. and Houchen, C.W. 2008. Distinguishing quiescent stem cells from cycling progenitor cells in intestinal crypts with the recently identified novel markers DCAMKL-1 and Lgr5. Abstract submitted for Digestive Disease Week, San Diego, April 2008 (*Gastroenterology*. 2008;134(4):A-96).
22. **Sureban, S.M.,** May, R., George, R., Dieckgraefe, B.K., Anant, S. and Houchen, C.W. Knockdown of Musashi-1 results in $p21^{waf-1}$ induction during G_2/M arrest and mitotic catastrophe via inhibition of Notch signaling. Abstract submitted for Digestive Disease Week, San Diego, April 2008 (*Gastroenterology*. 2008;134(4):A-86).

23. **Sureban, S.M.,** George, R., May, R., Dieckgraefe, B.K., Anant, S. and Houchen, C.W. RNA binding protein Musashi-1 (Msi-1) is an important regulator of tumor growth. Abstract submitted for Digestive Disease Week, Washington DC, April 2007 (*Gastroenterology*. 2007;132(4):A-154).

24. **Sureban, S.M.,** Morrison A., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. EGF induces COX-2 expression through increased polysome association: Potential role of protooncogene RBM3. Abstract submitted for Digestive Disease Week, Washington DC, April 2007 (*Gastroenterology*. 2007;132(4):A-54).

25. Lee, K.B., Subramaniam, D., **Sureban, S.M.,** Ramanujam, R., Kalman, H., Kuppusamy, P., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. Novel curcumin analog diphenyl difluoroketone (L-2395) mediates anti-colon cancer activity through epidermal growth factor receptor signaling inhibition. Abstract submitted for Digestive Disease Week, Los Angeles, CA, April 2006 (*Gastroenterology*. 2006;130(4):A-118).

26. **Sureban, S.M.,** Subramaniam, D., Lee, K.B., Ramalingam, S., Morrison, A.M., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. Posttranscriptional regulation of COX-2 gene expression in intestinal tumorigenesis: Role of novel protooncogene RBM3. Abstract submitted for Digestive Disease Week, Los Angeles, CA, April 2006 (*Gastroenterology*. 2006;130(4):A-131).
Recipient of Fellow abstract of the year award for 2006 from AGA/FDHN.
Recipient of Fellow Travel award for 2006 from AGA/GRG.

27. **Sureban, S.M.,** Means, J.M., Murmu, N., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. Direct interaction between RNA binding proteins HuR and CUGBP2: functional antagonism in intestinal epithelial cells. Abstract submitted for Digestive Disease Week, Los Angeles, CA, April 2006 (*Gastroenterology*. 2006;130(4):A-131).

28. **Sureban, S.M.,** Maheshwari, R., Murmu, N., Dieckgraefe, B.K., Berg, D.E. and Anant, S., RNA binding proteins CUGBP2 and HuR compete for interacting with AU-rich sequences: Implications for COX-2 mRNA translation. Digestive Disease Week, Chicago, IL, April 2005 (*Gastroenterology*. 2005;128(4):A-141).

29. **Sureban, S.M.,** Rajendran, P., Subramaniam, D., Kanthesh, B.M., Rajendran, M., Dieckgraefe, B.K., Thyagarajan, S.P. and Anant, S. Hepatocyte gene expression and its regulation by Phyllanthus extracts: Role of Hepatitis B virus surface antigen. Annual Meeting of Indian Association of Anatomists, Salem, India, 2004.

30. **Sureban, S.M.,** Rajendran, P., Subramaniam, D., Thyagarajan, S.P., Dieckgraefe, B.K. and Anant, S. Antiviral and antiproliferative properties of *Phyllanthus* species: differential gene expression in hepatocytes dependent on HBsAg production. 25th Annual Conference of the Indian Association of Biomedical Scientists, Chennai, India, 2004.

31. **Sureban, S.M.,** Balakrishnan, A.K., Dieckgraefe, B.K. and Anant, S. Inhibitory effect of the plant flavonoid galangin on TNF-alpha-mediated induction of interleukin-8 gene expression. 25th Annual Conference of the Indian Association of Biomedical Scientists, Chennai, India, 2004.

Recipient of Indira Vasudevan Award from Indian Association of Biomedical Scientists.

32. **Sureban, S.M.** and Thyagarajan, S.P. Geographical and Seasonal variation in *Phyllanthus amarus* versus its Clinical efficacy. International Conference on Indian Systems of Medicines and Homeopathy, Chennai, India, 2003.

33. **Sureban, S.M.** and Thyagarajan, S.P. Geographical and Seasonal variation in *Phyllanthus amarus* versus its Bio-efficacy. Indian Association of the Study of the Liver-European Association for the Study of the Liver, New Delhi, India, 2002.

34. **Sureban, S.M.** and Thyagarajan, S.P. Anti-Hepatitis B activity *Phyllanthus amarus*: Biologically standardised extract. XXVI Annual Congress Indian Association of Medical Microbiologists, Bangalore, India, 2002.

35. **Sureban, S.M.** and Thyagarajan, S.P. Standardisation of *Phyllanthus amarus*. XXV National Congress Indian Association of Medical Microbiologist, New Delhi, India, 2001.

F. Abstract presented as poster (Presenter underlined) (Sureban, S.M., presented 11 out of total 39 presentations – 2 poster of distinction awards):

1. Qu, D., Chandrakesan, P., Johnson, J., Weygant, N., May, R., Rhim, A., Stanger, B., **Sureban, S.M.,** and Houchen, C.W. Serum DCLK1 levels are elevated in early stage pancreatic cancer patients. Abstract submitted for American Pancreatic Association Conference, Hawaii, November 2014 (*Pancreas* 2014;43(8):1402).

2. **Sureban, S.M.,** May, R., Qu, D., Chandrakesan, P., Ali, N. and Houchen, C.W. RNA binding protein Musashi-1 regulates tumorigenesis and angiogenesis *via* microRNA-dependent mechanism. Abstract submitted for Digestive Disease Week, Chicago, IL, May 2014. (*Gastroenterology* 2014;146(5):S-488).

3. Chandrakesan, P., May, R., **Sureban, S.M.,** Qu, D., Weygant, N., Ali, N., Owen, D. and Houchen, C.W. Dclk1 regulates intestinal epithelial self-renewal, survival signaling pathways and DNA repair machinery in response to genotoxic injury. Abstract submitted for Digestive Disease Week, Chicago, IL, May 2014. (*Gastroenterology* 2014;146(5):S-786).

4. May, R., Qu, D., Weygant, N., Chandrakesan, P., **Sureban, S.M.,** Ali, N. and Houchen, C.W. Ablation of mesenchymal Dclk1 by the Foxl1-Cre promoter results in increased epithelial Tuft cells. Abstract submitted for Digestive Disease Week, Chicago, IL, May 2014. (*Gastroenterology* 2014;146(5):S-518).

5. Weygant, N., Qu, D., Berry, W.L., May, R., Chandrakesan, P., Owen, D., **Sureban, S.M.,** Ali, N., Janknecht, R. and Houchen, C.W. Small-molecule Parkinson's disease kinase inhibitor LRRK2-IN-1 demonstrates potent anti-cancer activity through inhibition of DCLK1. Abstract submitted for Digestive Disease Week, Chicago, IL, May 2014. (*Gastroenterology* 2014;146(5):S-694).

6. Chandrakesan, P., Weygant, N., May, R., Qu, D., **Sureban, S.M.,** Ali, N., Owen, D. and Houchen, C.W. Dclk1 enhances epithelial pluripotency and oncogenic signaling during intestinal tumor progression. Abstract submitted for Digestive Disease Week, Chicago, IL, May 2014. (*Gastroenterology* 2014;146(5):S-820).

7. Nguyen, C., Kotturi, H., **Sureban, S.M.,** May, R., Chandrakesan, P., Weygant N., Qu, D., Houchen, C.W. and Ali, N. Treimethoxy-cis-stilbene exhibits potent anti-tumor activities *via* suppression of AKT signaling and cell cycle arrest in virus-induced hepatocellular carcinoma. Abstract submitted for American Association for Cancer Research Annual Meeting, San Diego, CA, April 2014. (*Cancer Research* 2014;74(19):4552).

8. Qu, D., Weygant, N., May, R., Chandrakesan, P., Owen, D., **Sureban, S.M.** and Houchen, C.W. DCLK1 targeted monoclonal antibodies demonstrate therapeutic potential against pancreatic ductal adenocarcinoma. Abstract submitted for American Association for Cancer Research Annual Meeting, San Diego, CA, April 2014. (*Cancer Research* 2014;74(19):LB-48).

9. Ali, N., Chandrakesan, P., Huycke, M., Husain, S., Gillaspy, A.F., May, R., Berry, W.L., **Sureban, S.M.,** Qu, D., Weygant, N., Bronze, M., Dhanasekaran, D. and Houchen, C.W. Overexpression of doublecortin-like kinase (DCLK1) leads to activation of inflammatory cascade during development of virus-induced hepatocellular carcinoma. Abstract submitted for American Association for Cancer Research Annual Meeting, San Diego, CA, April 2014. (*Cancer Research* 2014;74(19):3171).

10. **Sureban, S.M.,** May, R., Weygant, N., Qu, D. and Houchen, C.W. Regulation of angiogenic factors by DCLK1 in pancreatic cancer. Abstract submitted for American Pancreatic Association Conference, Miami, November 2013. (*Pancreas* 2013;42(8):1384).

11. Qu, D., Weygant, N., Berry, R., Owen, D., **Sureban, S.M.** and Houchen, C.W. A kinase inhibitor specific for DCLK1 demonstrates therapeutic potential against human pancreatic adenocarcinoma cells. Abstract submitted for American Pancreatic Association Conference, Miami, November 2013. (*Pancreas* 2013;42(8):1378).

12. Qu, D., May, R., Chandrakesan, P., Weygant, N., **Sureban, S.M.,** Ali, N. and Houchen, C.W. Ablation of Dclk1 in intestinal epithelium exacerbates colonic epithelial barrier damage in response to DSS treatment. Abstract submitted for Digestive Disease Week, Orlando, May 2013. (*Gastroenterology* 2013;144(5):S-668).
Poster of distinction.

13. Shakir, F., May, R., **Sureban, S.M.,** Lightfoot, S.A., Madhoun, M. and Houchen, C.W. Expression of a novel stem cell marker Doublecortin-like kinase 1 (DCLK1) in human colorectal polyps and adenocarcinoma. Abstract submitted for Digestive Disease Week, Orlando, May 2013. (*Gastroenterology* 2013;144(5):S-876 – S877).
Poster of distinction.

14. May, R., Qu, D., Weygant, N., Chandrakesan, P., Ali, N., **Sureban, S.M.,** Lightfoot, S.A., Li, L. and Houchen, C.W. Dclk1 deletion in mouse small intestinal tuft cells results in impaired epithelial restoration following radiation injury. Abstract submitted for Digestive Disease Week, Orlando, May 2013. (*Gastroenterology* 2013;144(5):S-833 – S-834).

15. Ali, N., **Sureban, S.M.,** May, R., Allam, H., Bader, T., Bronze, M. and Houchen, C.W. A putative stem cell marker doublecortin-like kinase 1 (DCLK1) is involved in the development of hepatocellular carcinoma. Abstract submitted for American Association for Cancer Research Annual Meeting, Washington DC, April 2013. (*Cancer Research* 2013;73(8):4902).

16. Ramachandran, I., Obeso, D., **Sureban, S.M.,** Thavathiru, E., Reis, A. and Queimado, L. *microRNA-200c* mediates the tumor suppressive effects of Wnt inhibitory factor 1 in human malignant salivary gland cells. Abstract submitted for American Association for Cancer Research Annual Meeting, Washington DC, April 2013. (*Cancer Research* 2013;73(8):4298).

17. **Sureban, S.M.,** May, R., Qu, D., Ali, N. and Houchen, C.W. Regulation of pluripotency markers by DCLK1 in pancreatic cancer. Abstract submitted for American Pancreatic Association Conference, Miami, November 2012 (*Pancreas* 2012;41(8):1407) (*Pancreatology* 2013;13(2):e77).

18. **Sureban, S.M.,** Qu, D., May, R., Ali, N. and Houchen, C.W. DCAMKL-1 regulates pluripotency factors OCT4, SOX2 and KLF4 via *miR-145* microRNA dependent mechanism. Abstract submitted for Digestive Disease Week, San Diego, May 2012 (*Gastroenterology* 2012;142(5):S-523).

19. **Sureban, S.M.,** May, R., Qu, D., Weygant, N., Chandrakesan, P., Umar, S., Ramanujam R. and Houchen, C.W. Dietary pectin increases intestinal crypt stem cell survival following radiation injury. Abstract submitted for Digestive Disease Week, San Diego, May 2012 (*Gastroenterology* 2012;142(5):S-334).

20. Johnson, J.J, Qu, D., **Sureban, S.M.,** May, R., Lightfoot, S., Hassell, L., Pant, S., Postier, R.G. and Houchen, C.W. The expression of putative pancreatic stem cell marker DCAMKL-1 is elevated in early stage pancreatic adenocarcinoma patients. Abstract submitted for Digestive Disease Week, San Diego, May 2012 (*Gastroenterology* 2012;142(5):S-1086).

21. Chandrakesan, P., **Sureban, S.M.,** May, R., Weygant, N., Ali, N., Qu, D. and Houchen, C.W. Role of DCAMKL-1+ stem cells in epithelial-mesenchymal transition and intestinal neoplasia. Abstract submitted for Digestive Disease Week, San Diego, May 2012 (*Gastroenterology* 2012;142(5):S-517).

22. May, R., **Sureban, S.M.,** Qu, D., Weygant, N., Chandrakesan, P. and Houchen, C.W. Systemic delivery of nanoparticle-encapsulated siRNA targeting DCAMKL-1 results in reduced intestinal polyposis in *APC*$^{min/+}$ mice. Abstract submitted for Digestive Disease Week, San Diego, May 2012 (*Gastroenterology* 2012;142(5):S-329).

23. **Sureban, S.M.,** May, R., Qu, D., Anant, S. and Houchen, C.W. siRNA mediated blockade of DCAMKL-1 results in pancreatic tumor xenograft growth arrest by *let-7*a and *miR-200a* microRNAs-dependent mechanisms. Abstract submitted for American Pancreatic Association Conference, Chicago, November 2011 (*Pancreas* 2011;40(8):1356).

24. Whorton, J., Lightfoot, S., **Sureban, S.M.,** May, R., Qu, D., Madhoun, M., Tierney, W.M., Maple, J.T., Vega, K.J. and Houchen, C.W. DCAMKL-1 expression in Barrett's esophagus and esophageal adenocarcinoma. Abstract submitted for Digestive Disease Week, Chicago, May 2011 (*Gastroenterology* 2011;140(5):S-308).

25. Qu, D., **Sureban, S.M.,** May, R., Asfa, S., Meltzer, S.J., Anant, S. and Houchen, C.W. Comparative evaluation of novel putative stem cell markers and tumor suppressor microRNAs in Barrett's esophagus. Abstract submitted for Digestive Disease Week, Chicago, May 2011 (*Gastroenterology* 2011;140(5):S-224).

26. Ali, N., Allam, H., May, R., **Sureban, S.M.,** Anant, S., Bronze, M.S., Umar, S. and Houchen, C.W. Role of Doublecortin and CaM Kinase-like-1 (DCAMKL-1) in Hepatitis C Virus-induced hepatocarcinogenesis. Abstract submitted for Digestive Disease Week, Chicago, May 2011 (*Gastroenterology* 2011;140(5):S-972).

27. **Sureban, S.M.,** May, R., Mondalek, F.G., Ponnurangam, S., Qu, D., Pantazis, P., Ramanujam, R., Anant, S. and Houchen, C.W. Nanoparticle-based delivery of siDCAMKL-1 increases *microRNA-200a* and inhibits colorectal cancer tumor growth and epithelial-mesenchymal transition. Keystone Symposia 'Stem cells, Cancer and Metastasis', Keystone Resort, Keystone, Colorado, March 2011.

28. **Sureban, S.M.,** May, R., Lightfoot, S.A., Wyche, J.H., Anant, S. and Houchen, C.W. Putative pancreatic cancer stem cell marker DCAMKL-1: Role in EMT. Abstract submitted for American Pancreatic Association Conference, Chicago, November 2010 (*Pancreas* 2010;39(8):1349).

29. May, R., **Sureban, S.M.,** Lightfoot, S.A., Wyche, J.H., Anant, S. and Houchen, C.W. Inhibition of Notch signaling decreases intestinal stem cell survival following radiation injury. Abstract submitted for Digestive Disease Week, New Orleans, May 2010 (*Gastroenterology* 2010;138(5):S-253).

30. May, R., **Sureban, SM.,** Lightfoot, S.A., Anant, S. and Houchen, C.W. 2009. Identification of a novel pancreatic stem cell marker DCAMKL-1 in mouse pancreas and pancreatic cancer. FASEB conference Aug 2009.

31. **Sureban, S.M.,** May, R., Ramalingam, S., Subramaniam, D., Natarajan, G., Wyche, J.H., Anant, S. and Houchen, C.W. Selective blockade of DCAMKL-1 results in tumor growth arrest By a *let-7a* microRNA dependent mechanism. Abstract submitted for Digestive Disease Week, Chicago, May 2009 (*Gastroenterology* 2009;136(5):A298).

32. Roberts, D., Bader, T., Berry, W., **Sureban, S.M.** and Anant, S. Statin enhances cisplatin induced effect on hepatoma cell lines. Abstract submitted for American College of Gastroenterology conference, Orlando, Sept 2008 (*American Journal of Gastroenterology* 2008;103:S161).

33. Subramainam, D., Ramalingam, S., Stoner, G.D., **Sureban, S.M.,** Houchen, C.W., Ramanujam, R. and Anant, S. A novel *in vitro* detection method to identify dietary chemopreventive agents utilizing the NF-kB pathway. Abstract submitted for Digestive Disease Week, San Diego, April 2008 (*Gastroenterology* 2008;134(4):A286).

34. Draper, M., **Sureban, S.M.,** Ramalingam, S., Natarajan, G., Houchen, C.W. and Anant, S. Epidermal Growth Factor induces expression of protooncogene RBM3 through p38 and Erk resulting in increased COX-2 expression. Abstract submitted for Digestive Disease Week, San Diego, April 2008 (*Gastroenterology*. Vol. 134, Issue 4, Page A241).

35. Subramaniam, D., **Sureban, S.M.,** George, R., Ramanujam, R., Kalman, H., Kuppusamy, P., Dieckgraefe, B.K., Houchen, C.W. and Anant, S. A novel synthetic diphenyl, difluoroketone compound (L-2395) with potent *in vitro* and *in vivo* anti-cancer activity. Abstract submitted for Digestive Disease Week, Los Angeles, CA, April 2006 (*Gastroenterology* 2006;130(4):A-580).

36. Murmu, N., Gross, S., **Sureban, S.M.,** Subramaniam, D., Dieckgraefe, B.K., Piwnica-Worms, D. and Anant, S. P50 External Review Poster session, Saint Louis, MO, 2005.

37. Murmu, N., Gross, S., **Sureban, S.M.,** Dieckgraefe, B.K., Piwnica-Worms, D. and Anant, S. Bioluminescent imaging of IkB activity and screening for potent inhibitory activity by dietary compounds. Third Annual Meeting of the Society for Molecular Imaging, St. Louis, MO, 2004.

38. **Sureban, S.M.,** Rajendran, P., Subramaniam, D., Dieckgraefe, B.K., Thyagarajan, S.P. and Anant, S. Chemotherapeutic effects of *Phyllanthus* species: molecular and cellular response to anti-viral agents. Asian Pacific Association for the Study of Liver Conference, New Delhi, 2004. *Journal of Gastroenterology and Hepatology* 2004;19(Suppl.).

39. **Sureban, S.M.,** Murmu, N., Maheshwari, R., Bishnupuri K.S., Houchen, C., Dieckgraefe, B.K. and Anant, S. Dietary phytochemicals as novel therapeutics in IBD. Poster Presentation, APS Translational Research Conference: Immunological and Pathophysiological Mechanisms in Inflammatory Bowel Disease, Snowmass, CO, 2004.

Completed and On-going Projects lead by Dr. Sureban:

1. DCLK1 regulates angiogenic factors VEGFR1 and VEGFR2 and invasion/migration via *miR-200* microRNA dependent mechanism. December 2012 to present.
2. Dietary pectin increases intestinal crypt stem cell survival following radiation injury. Jun 2012 to present.
3. Small molecule kinase inhibitors XMD8-92 and PV1019 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. July 2012 to present.
4. DCAMKL-1/DCLK1 regulates pluripotency factors OCT4, SOX2 and KLF4 via *miR-145* microRNA dependent mechanism. June 2011 to present.
5. siRNA-mediated knockdown of DCAMKL-1/DCLK1 enhances *miR-144* and *miR-200a* and inhibits Notch-1 and epithelial-mesenchymal transition respectively in colorectal and pancreatic cancer. Aug 2008 to present.
6. Role of DCAMKL-1/DCLK1 in human pancreatic and liver cancer. Dec 2009 to present.
7. Selective blockade of DCAMKL-1 enhances *let-7a* tumor suppressor microRNA processing. Aug 2008 to present.
8. Identification of a novel intestinal and pancreatic stem cell marker DCAMKL-1. Jun 2007 to present.
9. Knockdown of RNA binding protein musashi-1 (Msi-1) leads to tumor regression *in vivo*. January 2006 to present.
10. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. November 2003 to June 2008.
11. Functional antagonism between HuR and CUGBP2 determines the fate of COX-2 mRNA translation. Project funded by National Institute of Health – November 2003 to Mar 2007.
12. Evaluation of Siddha Medicine formulation for HIV and Hepatitis B. Funded by Shaptharishi Research Medical foundation, Chennai – December 2002 to October 2003.
13. Standardisation and evaluation of *Phyllanthus amarus* preparation. Funded by Rallis India Ltd., Mumbai and Phytopharm Plc., UK. – Dec 1999 to April 2001. Funded by Amadeus Biotech & Pharmaceuticals, Mumbai – April 2001 to October 2003.

14. Isolation and Standardisation of Markers from *Phyllanthus amarus*. Funded by Natural Remedies Pvt. Ltd. – January 1999 to November 1999. M. Pharmacy Dissertation – Submitted to Rajiv Gandhi University of Health Sciences, Bangalore.